AV-GBM-1 Emerging Drug Insight and Market Forecast - 2032

“"AV-GBM-1 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AV-GBM-1 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the AV-GBM-1 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AV-GBM-1 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AV-GBM-1 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

AV-GBM-1 is novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens derived from self-renewing tumor-initiating cells derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. The treatment is administered in a series of SC injections as adjunctive therapy. It is uniquely pan-antigenic, targeting multiple antigens on autologous tumor-initiating cells responsible for the rapid growth of the disease and resistance to standard therapy. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.

Aivita Biomedical investigates AV-GBM-1 as a potential treatment for newly diagnosed GBM in Phase III clinical trial.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AV-GBM-1 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on AV-GBM-1 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AV-GBM-1 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AV-GBM-1.
• The report contains forecasted sales of AV-GBM-1 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for AV-GBM-1 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AV-GBM-1 Analytical Perspective by DelveInsight

In-depth AV-GBM-1 Market Assessment

This report provides a detailed market assessment of AV-GBM-1 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

AV-GBM-1 Clinical Assessment

The report provides the clinical trials information of AV-GBM-1 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AV-GBM-1 dominance.
• Other emerging products for GBM are expected to give tough market competition to AV-GBM-1 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AV-GBM-1 in GBM.
• Our in-depth analysis of the forecasted sales data of AV-GBM-1 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AV-GBM-1 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of AV-GBM-1?
• What is the clinical trial status of the study related to AV-GBM-1 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AV-GBM-1 development?
• What are the key designations that have been granted to AV-GBM-1 for GBM?
• What is the forecasted market scenario of AV-GBM-1 for GBM?
• What are the forecasted sales of AV-GBM-1 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to AV-GBM-1 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?